newsfilter
← Latest News
GlobeNewswire·

Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update

Further analysis of results from recently-completed SUMMIT Phase 3 efficacy trial of STS101 for the acute treatment of migraine shows differentiating robust and sustained antimigraine effects on clinically important